📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2017)

First Author: Graham C
Attributed to:  BRIC: Packaging cell lines for inherently manufacturable viral vectors funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood.v130.suppl_1.887.887

Publication URI: http://dx.doi.org/10.1182/blood.v130.suppl_1.887.887

Type: Journal Article/Review

Parent Publication: Blood

Issue: Suppl_1